In diabetic ApoE-/- mice, canagliflozin was reported to protect endothelial function and reduce the incidence of atherosclerosis by decreasing aortic Nox2 and p22phox expression and urinary 8-OHdG excretion to minimize oxidative stress and considerably reduced aortic ICAM-1 and VCAM-1 expression [127]. The gene discussed is CYBB; the disease is atherosclerosis.